Abivax S.A. (ABVX) stock
ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
$82.10−1.51 (-1.81%)
Close on Nov 17, 2026Market cap $6.45BP/E –Yield –
Abivax operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Abivax's operating income for the twelve months ending Jun 30, 2026 was -€292.70M. For fiscal 2025 it was -€246.06M. The highest annual figure on record is -€41.40M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€246.06M | – |
| FY2024 | Dec 31, 2024 | -€172.98M | – |
| FY2023 | Dec 31, 2023 | -€127.38M | – |
| FY2022 | Dec 31, 2022 | -€64.84M | – |
| FY2021 | Dec 31, 2021 | -€41.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€84.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -€56.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -€71.65M | – |
| Q3 FY2025 | Sep 30, 2025 | -€80.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -€46.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -€47.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -€42.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -€50.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -€35.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -€44.67M | – |
See a number that looks wrong?